crohn’s disease News
-
G-Tech Medical’s Lindsay Axelrod Presents Her Abstract
G-Tech Medical’s Lindsay Axelrod presented her abstract with preliminary findings from an ongoing collaborative study with Stanford University supported by the Helmsley Charitable Trust. The study involves using non-invasive wireless electrode patches to read myoelectrical signals from the gut over 3 days in patients with Crohn’s disease. Forty patients presenting in flare, and 30 in ...
-
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
-
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IBD). This is the first ...
By CytoReason
-
Creative Proteomics Lipidomics Platform Boosts Short Chain Fatty Acids Research
Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, and biotechnological and pharmaceutical companies. The Lipidomics platform now employs gas chromatography-mass spectrometry (GC-MS) methods to enable fast and accurate qualitative and quantitative analysis of a ...
-
Discovery of an anti-inflammatory molecule produced by gut bacteria
Researchers at INRA, INSERM, AP-HP, and UPMC have just discovered a new protein with anti-inflammatory properties, which has been named MAM (microbial anti-inflammatory molecule). It is secreted by the bacterium Faecalibacterium prausnitzii and helps fight intestinal inflammation. This discovery, recently published in the journal Gut, is a major advance in efforts to develop new means of treating ...
-
Who can benefit from an adjustable gastric band implant?
Who can benefit from an adjustable gastric band implant? Adults between the ages of 18 and 60 years with morbid obesity (BMI of > 40) or severe obesity (BMI of > 35) with at least one complication (diabetes, hypertension, sleep apnea syndrome, joint disorders) People who have already tried to lose weight without success despite receiving specialized medical care for several months ...
-
SFA Therapeutics, Inc. announces start of phase 1B clinical trial in the treatment of mild-to-moderate plaque psoriasis
SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to psoriasis.” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial. This 30-subject open-label clinical trial in patients with ...
-
Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...
-
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
-
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in ...
-
Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
SG-5-00455, the Company’s development candidate for the treatment of IBD, aims to restore mucosal healing by targeting PAI-1/2 Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, yesterday hosted a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator ...
-
Runway Growth Capital Announces a Senior Secured Term Loan of $35 Million to SetPoint Medical
Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies seeking an alternative to raising equity, today announced the close of a senior secured term loan of $35 million to SetPoint Medical (“SetPoint”), a Valencia, California based, privately-held clinical-stage bioelectronic medicine company developing ...
-
Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule. In preclinical testing, RaniPill HC demonstrated successful delivery of adalimumab and achieved high bioavailability. “The ...
-
INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market
INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate cancer diagnostics and INOVIQ is developing a multi-product ...
By INOVIQ Ltd
-
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
Galapagos NV (Euronext & NASDAQ: GLPG) today held its R&D Day 2022, featuring presentations of key opinion leaders and company management on the strategic, scientific, and commercial progress at the company. The company also presented its financial results for the third quarter of 2022. Paul Stoffels3, CEO and Chairman of the Board of Directors of Galapagos, commented: “Today we ...
By Galapagos NV
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you